Insider Selling: Scott D. Sandell Sells 1,430 Shares of Hyperion Therapeutics Stock (HPTX)
Hyperion Therapeutics (NASDAQ:HPTX) major shareholder Scott D. Sandell sold 1,430 shares of Hyperion Therapeutics stock on the open market in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $5.54, for a total value of $7,922.20. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Hyperion Therapeutics (NASDAQ:HPTX) traded up 2.04% during mid-day trading on Monday, hitting $27.50. The stock had a trading volume of 148,353 shares. Hyperion Therapeutics has a one year low of $18.22 and a one year high of $32.98. The stock has a 50-day moving average of $25.92 and a 200-day moving average of $25.7. The company has a market cap of $557.3 million and a P/E ratio of 21.80.
Hyperion Therapeutics (NASDAQ:HPTX) last announced its earnings results on Tuesday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter. On average, analysts predict that Hyperion Therapeutics will post $-0.23 earnings per share for the current fiscal year.
HPTX has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Hyperion Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, April 29th. They now have a $25.20 price target on the stock. Analysts at Cantor Fitzgerald initiated coverage on shares of Hyperion Therapeutics in a research note on Tuesday, March 18th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $34.84.
Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.